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Label retention and stem cell marker
expression in the developing and adult
prostate identifies basal and luminal
epithelial stem cell subpopulations
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Abstract
Background: Prostate cancer is the second most frequent cancer among males worldwide, and most patients with
metastatic disease eventually develop therapy-resistant disease. Recent research has suggested the existence of
cancer stem-like cells, and that such cells are behind the therapy resistance and progression.
Methods: Here, we have taken advantage of the relatively quiescent nature of stem cells to identify the slow-
cycling label-retaining stem cell (LRC) populations of the prostate gland. Mice were pulsed with bromodeoxyuridine
(BrdU) during prostate organogenesis, and the LRC populations were then identified and characterized in 5-day-old
and in 6-month-old adult animals using immunohistochemistry and immunofluorescence.
Results: Quantification of LRCs in the adult mouse prostate showed that epithelial LRCs were significantly more
numerous in prostatic ducts (3.7 ± 0.47% SD) when compared to the proximal (1.4 ± 0.83%) and distal epithelium
(0.48 ± 0.08%) of the secretory lobes. LRCs were identified in both the basal and epithelial cell layers of the prostate,
and LRCs co-expressed several candidate stem cell markers in a developmental and duct/acini-specific manner,
including Sca-1, TROP-2, CD133, CD44, c-kit, and the novel prostate progenitor marker cytokeratin-7. Importantly, a
significant proportion of LRCs were localized in the luminal cell layer, the majority in ducts and the proximal
prostate, that co-expressed high levels of androgen receptor in the adult prostate.
Conclusions: Our results suggest that there are separate basal and luminal stem cell populations in the prostate,
and they open up the possibility that androgen receptor-expressing luminal stem-like cells could function as
cancer-initiating and relapse-responsible cells in prostate cancer.
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Background
Prostate cancer (PCa) is the second most frequent can-
cer among males worldwide [14]. Although almost all
patients with metastatic PCa initially respond to andro-
gen deprivation therapy (surgical or medical castration),
nearly all patients eventually develop progressive
castration-resistant disease; death from PCa is invari-
ably due to resistance to contemporary treatment
modalities [17].
Prostate carcinogenesis and the mechanisms respon-
sible for castration-resistant tumor growth are incom-
pletely understood. Research from hematopoietic and
solid tumors have suggested the existence of stem-like
cancer cells, termed cancer stem cells (CSCs), that are
believed to be involved in tumor initiation, metastatic
spread, therapy resistance, and progression [30]. Much
research is now focused on identifying and characteriz-
ing this critical cell population(s) in order to develop
more effective therapies.
It has been suggested that tumor-initiating cells of
prostate adenocarcinoma originate from adult stem cells
(SCs) present in the basal epithelial cell layer of the
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prostate [9, 21, 34, 40]. It is, however, not known
whether CSCs are transformed SCs, or differentiated
cancer cells that gain self-renewal capacity, or if prostate
luminal SCs exists in addition to basal SCs.
The prostate glandular tissue develops from the out-
growing buds of the embryonic urogenital sinus epithe-
lium during prostate organogenesis [32]. It is believed
that SCs in the androgen receptor-negative urogenital
sinus epithelium initiate budding in response to urogeni-
tal sinus mesenchymal growth factors, triggered by the
rise of testicular androgens during development [35, 39].
Cells in the basal layer of the mouse prostate have been
shown to possess self-renewal capability and can gener-
ate all three cell lineages of the prostate epithelium, in-
cluding basal, secretory luminal, and neuroendocrine
cells [26]. The location and identity of SCs in the adult
prostate remains controversial, though, and cells with
basal, neuroendocrine, and luminal phenotypes all sur-
vive castration to different degrees in PCa patients [15,
37], suggesting that stem-like luminal or neuroendo-
crine cells may also exist and serve as tumor-initiating
or relapse-initiating cells in castration-resistant tumors
[12, 20, 27, 31].
A distinctly robust method for identifying tissue SCs
takes advantage of the relatively quiescent nature of SCs,
where cells are pulsed with a label such as the thymidine
nucleoside analog bromodeoxyuridine (BrdU) [1, 4, 16,
22]. Whereas rapidly proliferating, transit-amplifying, and
maturing cells will dilute the label during a prolonged
chase period, slow-cycling SCs will retain the label and
they can then be identified as the label-retaining cells
(LRCs). Label retention has been used to identify tissue
SCs in many various tissues, including intestine, hair folli-
cles, kidney, and the breast [4, 5, 7, 10, 18, 24].
In an attempt to clarify the identity and the location of
slow-cycling prostate epithelial tissue SCs, we examined
the location of LRCs in the developing and adult mouse
prostate in conjunction with cell lineage markers and
candidate stem cell antigens. We hypothesized that a
critical proliferative window for maximal labeling of epi-
thelial stem cells would be at the time of embryonic
prostate bud induction since this is the time period
when epithelial SCs in the urogenital sinus should prolif-
erate to initiate prostate budding. We pulsed embryos in
utero with BrdU during this phase, and then chased the
cells until after birth and adulthood. We found that a
significant proportion of epithelial cells in the prostate
lobes retained BrdU and that the highest frequency of
LRCs was to be found in the prostate ducts. LRCs were
identified in both the basal and epithelial cell layers of
the prostate, expressing candidate SC markers in a de-
velopmental and duct/acini-specific manner, including
the novel prostate SC marker cytokeratin-7 (KRT-7). Im-
portantly, luminal LRCs were identified to express
androgen receptor (AR) and KRT-7, and to be present in
decreasing frequency from ducts to secretory lobes.
Current results suggest that there are separate basal and
luminal prostate SC populations, and support the idea
that stem-like AR-expressing luminal cells could func-
tion as cancer-initiating and relapse-initiating cells in
prostate cancer.
Methods
Mouse label retention model
CD1 mice (Mus musculus) were supplied by Harlan
Laboratories and bred at the central animal laboratory
(CDL) of Radboud University Medical Center, Nijmegen,
the Netherlands. The animal study was approved by the
Animal Ethics Committee (DEC) at Radboud University.
For generation of BrdU-labeled embryos, six pregnant
CD1 mice were injected subcutaneously at embryonic
days 16.5 (E16.5) and E17.5 with BrdU (50 μg/g) diluted
in phosphate-buffered saline (PBS) in the posterior neck,
giving rise to 29 BrdU-labeled male offspring that were
euthanized 5 days postnatally (P5) or 6 months after
birth (adult). Additionally, offspring from nonlabeled
pregnant mice were euthanized (E18.5, P0, P5, and adult;
three to twelve males per group). Prostates were then
dissected out and either freshly snap frozen in OCT
(Tissue-Tek, Sakura, the Netherlands) or fixed (1 h/mm
tissue) in 4% paraformaldehyde in PBS and embedded in
paraffin according to standard procedure.
Immunohistochemistry and immunofluorescence
Paraffin- and OCT-embedded specimens were cut into
4-μm thick sections, mounted on SuperFrost Plus slides
(Menzel Gläser, Braunschweig, Germany), and subse-
quently deparaffinized and rehydrated (according to
standard immunohistochemical protocols), or fixed in ei-
ther 4% paraformaldehyde or ice-cold methanol for 10
min (cryosections). Paraffin rehydrated specimens were
subjected to antigen retrieval (boiling in 10 mM sodium
citrate buffer, pH 6.0, for 10 min). For chromogenic
immunohistochemistry (IHC), endogenous peroxidase
activity was blocked with 0.3% H2O2 and 0.1% NaN3 in
PBS (pH 7.4) for 20 min, and avidin/biotin-binding sites
were blocked with an avidin/biotin blocking kit accord-
ing to the manufacturer’s instructions (Vector Labora-
tories, CA, USA) before each single or sequential
(double) staining. For BrdU detection, sections were sub-
jected to acid treatment (10 min incubation in 1 N HCl
on ice, followed by 10 min in 2 N HCl at room
temperature, and then 30 min in 2 N HCl at 60 °C)
followed by incubation in borate buffer (0.1 M, pH 8.5,
12 min), either before or after blocking (5% normal
serum in PBS) and incubation with primary antibodies
(diluted in PBS with 1% normal serum). IHC detection
was performed sequentially with BrdU detection last,
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whereas immunofluorescence (IF) was performed by co-
incubating primary antibodies against BrdU and
endogenous antigens after the acid treatment step. How-
ever, the epitope of c-kit was sensitive to the low pH of
the acid treatment, and slides were therefore blocked
and incubated overnight with the primary antibody prior
to the acid and borate treatment. Additionally, a postin-
cubation fixation step (4% paraformaldehyde in PBS, 10
min) was performed immediately after incubation with
the primary antibody and washing (PBS). Slides were de-
tected with primary or secondary antibodies (Additional
file 1: Supplementary material and methods 1) conju-
gated with either Alexa-594/488 fluorescent dyes, HRP,
or with biotin, followed with streptavidin-AP/HRP com-
plexes as necessary, and developed using NBT/BCIP
(Roche Applied Science, Mannheim, Germany) and DAB
bright (ImmunoLogic, Duiven, the Netherlands) as chro-
mogens according to manufacturer’s instructions and
standard immunohistochemical methods. Counterstain-
ing was performed with DAPI (Life Technologies, USA)
or hematoxylin (HTX; Vector Laboratories), and cover-
slipped with Prolong Gold (Life Technologies, USA) or
with Permount (Vector Laboratories) after dehydration.
As a negative control, nonlabeled mouse prostates were
used for BrdU, and primary antibodies were omitted for
endogenous antigens. The kidney, colon, and testes were
used as positive controls (Additional file 2: Figure S1).
Additionally, preabsorption using immunizing AR peptide
(sc-816 P, Santa Cruz Biotechnology, TX, USA) was per-
formed. Slides were evaluated with light and fluorescent
microscopy (Olympus AX70, Leica DC 300 F) and scanned
with a high-content microscope (Leica DM16000B).
Quantitative analysis of LRCs and cellular proliferation
Label-retaining and proliferative indexes were calcu-
lated from adult prostates double-stained for BrdU/p63
and Ki67/p63, respectively. The mouse prostates were
divided into three regions—ductal, proximal, and
distal—for the LRC index, and into two regions for the
proliferation index—distal epithelium versus ductal-
proximal epithelium. Random high-power magnifica-
tion fields of epithelium from each region from at least
three specimens were quantitated. At least 8000 epithe-
lial cells were counted for each index. The fraction of
total, basal, and luminal LRCs in each region was calcu-
lated by dividing the number of BrdU-positive cells by
the total amount of epithelial cells, and number of
double BrdU/p63-positive cells by number of p63-positive
basal cells, and number of BrdU-positive but p63-negative
luminal cells by the number of p63-negative luminal cells
in each region. Similar calculations were performed for
total, basal, and luminal fractions of proliferating cells in
the two regions for Ki67- and p63-stained sections.
Statistical comparisons between groups were performed
using two-tailed Z tests for two population proportions.
Results
Proliferation and SC markers are inversely expressed
during early prostate development
In male CD1 mice (21 days of gestation), phenotypic
prostate glandular development starts with epithelial
budding into the mesenchyme at fetal day 17.5. We
pulse-chased mice with the synthetic thymidine analog
BrdU in order to identify the prostate SC populations.
To increase the uptake of the label into the nucleic acid
of SCs and to maximize the wash-out of the label in
non-SCs, we posited that the label should be given at
the time of induction of prostate SC proliferation and
epithelial budding, and when few cell divisions have oc-
curred in the developing organ. Additionally, we hypoth-
esized that epithelial SC proliferation may commence
prior to phenotypic budding, and hence we chose to
start our 2-day label protocol 24 h before morphological
budding had occurred, thus labeling animals at E16.5
and at E17.5. The presence of LRCs was then investi-
gated in 5-day-old (P5) prostates, a developmental stage
where most of the epithelial branching has occurred,
and in adult animals, to investigate if LRCs are long-
lived.
Since many proteins were sensitive to the harsh treat-
ment of the BrdU detection protocol, we first screened
prostates from nonlabeled embryonic and newborn
animals for potential SC marker expression during early
development in conjunction with the proliferative
marker Ki67. The mouse prostate comprises four paired
(right-left) lobes (the ventral prostate (VP), anterior
prostate (AP), lateral prostate (LP), and dorsal prostate
(DP); the DP and LP are often grouped together as the
DLP) that are located circumferentially around the ur-
ethra, where the excretory ducts fuse with the urethral
lumen, or, in the case of the DLP, with the urethral
lumen and with the ejaculatory sinus (ES) (the ES drains
into the urethra and is formed by the fusion of the ter-
minal ducts of the seminal vesicle and the terminal por-
tion of the vas deferens, the paired ejaculatory ducts).
During prostate organogenesis, the principal epithelial
ducts arise from these urethral/periurethral structures
and, in accordance with previous results, we found that
epithelial buds were negative for AR expression in E18.5
prostates, whereas the mesenchyme abundantly expressed
AR (Fig. 1a). During later development, the epithelial buds
give rise to tributary ducts that branch further and form
the arborized glandular secretory lobes. In newborn pros-
tates (P0), basally located cells of ducts expressed the adult
basal cell lineage marker p63 (Fig. 1b), and p63 was fur-
ther expressed by ‘luminally’ located cells of distal epithe-
lium of the lobes, including the VP (Fig. 1b, arrow), likely
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reflecting an undifferentiated state and the very high pro-
liferative activity (Fig. 1c, arrow) detected in the tip epithe-
lium (Fig. 1c–i). Expression of cytokeratin-8 (KRT-8), a
marker of mature luminal cells, was stronger in luminally
located cells of both ducts and distal epithelium, however
(Fig. 1c, arrowhead). Detection of the proliferative marker
Ki67 in P0 prostates indicated that proliferating cells were
more abundant in the distal tips in all four lobes, as com-
pared to the terminal portions of the ducts, proximal to
the urethra (Fig. 1c–i). A mostly inverse relationship was
found for several candidate SC markers, including TROP-
2 (Fig. 1d), Sca-1 (Fig. 1e), c-kit (Fig. 1h), and cytokeratin-
7 (KRT-7) (Fig. 1i), with stronger SC marker expression
proximally than distally, leaving the majority of proximal
SC marker-expressing cells negative for the proliferative
marker Ki67. However, rare proximal to intermediate lo-
cated cells positive for the above SC markers did co-stain
for Ki67 (Fig. 1i, arrow). In stark contrast, the putative SC
protein CD44 was not, or only very rarely, detected in
duct epithelium, but was abundantly expressed in distal
tips, where a large proportion of cells co-expressed CD44
and Ki67 (Fig. 1g). In addition, the VP expressed TROP-2
and Sca-1 abundantly in distal cells, preferentially lumin-
ally located (Fig. 1d and e), whereas the other lobes only
harbored rare cells positive for TROP-2, Sca-1, c-kit, and
KRT-7 in the distal epithelium. Several SC proteins further
showed a dual mesenchymal-epithelial expression pattern,
or were restricted entirely to the mesenchyme at this early
developmental stage. CD133 was expressed in the ES and
periurethral mesenchyme surrounding at least the prox-
imal part of the epithelial buds of all lobes (Fig. 1f, yellow
arrowheads). CD44 exhibited the same expression pattern
in proximal mesenchyme (Fig. 1g, yellow arrowheads) as
CD133, i.e., stronger proximally than distally, and inverse
to the epithelial expression pattern of CD44. The mesen-
chymal expression of c-kit was, on the other hand,
Fig. 1 IHC and IF analysis of cell lineage, SC markers, and proliferating cells in early developing mouse prostate. Sagittal sections of urogenital
sinus day E18.5 embryo (a) and sagittal sections of postnatal day P0 (b–i) were subjected to antibodies against AR (a; red), p63 (b; DAB), Ki67
(c–i; red), KRT-8 (c; green), TROP-2 (d; green), Sca-1 (e; green), CD133 (f; green), CD44 (g; green), c-kit (h; green), and KRT-7 (i; green). Note mesenchymal
AR expression (arrowheads) and absence of epithelial AR (arrows) during bud induction (a). Arrow in (b) shows p63 expression in ‘luminally’ located cells
of distal epithelium in newborn prostates. Note weak luminally located KRT-8 expression of both proximal (arrowheads) and distal epithelium (arrow, c).
Both TROP-2 and Sca-1 showed broader expression in the proximal AP (arrowhead, d, e) than in the distal AP (rightmost arrow, d, e) and distal DLP (left-
most arrow, d, e). Both markers, however, extended into the distal VP (lower arrow, d, e). CD133 expression was restricted to proximal periure-
thral mesenchyme (yellow arrowheads, f). CD44 was not, or only very rarely, detected in duct epithelium (arrowheads, g), but abundantly
expressed in proliferative (c–i) distal tips (arrows, g). Note proximal periurethral expression of CD44 in mesenchyme (yellow arrowheads, g). C-
kit was expressed in rare cells, preferentially located in proximal epithelium (arrowheads, h), the majority negative for Ki67 (arrows, h). Note a single
proliferating KRT-7-positive cell (arrow, i) at the proximal/intermediate border of the AP (arrowhead; proximal epithelium). Counterstaining when used
was either HTX (IHC) or DAPI (IF). Scale bars= 100 μm (a, f, h–i), 200 μm (c–e, g) and 500 μm (b); b is a composite image of several micrographs. In (b),
the ventral lobe (VP), anterior prostate (AP), dorso-lateral prostate (DLP), ejaculatory sinus (ES), and urethra (Ur) are indicated
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stronger in distal mesenchyme as compared to proximal
mesenchyme (Fig. 1h, and results not shown), with nu-
merous proliferating cells. Epithelial c-kit expression was
rare, and was preferentially located in terminal ducts
rather than in distal epithelium, with only exceptional co-
staining for Ki67 (Fig. 1h). At this stage, the urothelium of
the urethra was largely negative (<1%) for proliferating
cells (Fig. 1c–i).
LRCs and SC markers are enriched in the prostate ducts
Next we investigated the distribution of LRCs in postna-
tal day 5 (P5) prostates. The distribution of LRCs in
transversal sections of P5 prostates showed a proximal-
distal gradient (Fig. 2), with more numerous and more
strongly labeled cells in ducts (Fig. 2a and b) than when
compared to distal acinar structures of the prostatic
lobes (Fig. 2a and c). Whereas many urethral and ductal
LRCs would retain the label in the entire nucleus
(Fig. 2b), the BrdU content of the most distal LRCs de-
creased to parts or speckles in the nucleus (Fig. 2e).
However, rare LRCs in both the basal and luminal layer
of distal acini also retained BrdU in the entire nucleus
(Fig. 2c), with basal LRCs being more common than lu-
minal LRCs.
In P5 prostates, it was observed that the expression of
p63 was downregulated in most luminally located cells,
and almost entirely restricted to the basal cell layer of all
lobes (Fig. 2c). KRT-8 was also more highly expressed as
compared to earlier in development (results not shown),
and the AR was upregulated in terminal ducts (Fig. 2d),
but not, or only weakly so, in distal acini (Fig. 2e).
Interestingly, LRCs in the terminal ducts expressed AR
(Fig. 2d). In sagittal sections (Fig. 3), it was clearly dem-
onstrated that LRCs were more numerous and more
strongly labeled in terminal draining ducts in, or close
to, where the ES fuses with the urethra, whereas more
distal structures contained fewer and less bright LRCs
(Fig. 3h and k). This pattern was also reflected in the ex-
pression pattern of the putative SC markers Sca-1
(Fig. 3e, f, and i), TROP-2 (Fig. 3h), and KRT-7 (Fig. 3p),
with strong expression in the main ducts, but with an
abrupt downregulation where the ducts cross the apical
border of the sphincter urethrae muscle to enter the
prostate lobes (Fig. 3i and p). In the prostate lobes, these
markers were more rare, and typically strongest in lu-
minal cells (e.g., Fig. 3e). However, in the case of the VP
lobes, TROP-2 expression, albeit at lower levels than
ductal expression, extended some distance further into
the lobes proper (Fig. 3h). CD133 remained strongly
expressed in the mesenchyme surrounding the ES and
the draining prostate ducts of P5 prostates (Fig. 3g), but
was now mildly upregulated in the most distal epithe-
lium of the DLP (Fig. 3g, arrow). Likewise, CD44 was
highly expressed in proximal mesenchyme, but weakly
(Fig. 3j and k) in mesenchyme distal to the sphincter.
The inverse pattern was broadly seen for epithelial
CD44 expression, i.e., higher expression in distal epithe-
lium of the AP and DLP (Fig. 3k). However, CD44 was
downregulated in the distal luminal cells of the VP, but
remained strongly expressed in the basal cell layer of the
VP (Fig. 3k and l). Additionally, ducts of the VP now
had upregulated CD44 in the basal cell layer (Fig. 3k),
Fig. 2 IF analysis of the distribution of LRCs and co-expression of cell lineage markers in transversal sections of postnatal day 5 (P5) mouse
prostates. Paraffin sections were subjected to antibodies against BrdU (a–e; green), p63 (a–c), AR (d, e), and negative control (f). Note that both
basally (p63-positive; arrowheads) and luminally (p63-negative; arrows) located LRCs were more numerous and more strongly labeled in ducts
(a,b) than when compared to distal epithelium (a, c). In P5 prostates, AR was expressed in terminal ducts (d), and some of the strongest AR-expressing
cells co-expressed BrdU (arrow, d). However, distal acini (e) expressed no or only low levels of AR (arrowheads indicate stromal AR expression in d, e). DAPI
was used as counterstaining in a–e. Scale bars= 200 μm (a), 100 μm (f), and 50 μm (b–e)
Ceder et al. Stem Cell Research & Therapy  (2017) 8:95 Page 5 of 12
but with fewer CD44-positive cells where the ducts fuse
with the urethra (Fig. 3j). The stromal expression of c-kit
was, on the other hand, stronger distally to the sphincter
(Fig. 3n and o) than proximally (Fig. 3m), and was strongly
upregulated in the peri-glandular mesenchyme surround-
ing the epithelial cords of the DLP (Fig. 3n and o). LRCs
strongly reactive for BrdU in ductal and proximal epithe-
lium were positive for c-kit expression (Fig. 3m and o). No
LRCs positive for the neuroendocrine marker chromogra-
nin A could be identified (Additional file 2: Figure S1).
Long-lived LRCs are found in both basal and luminal
epithelium
Next we wanted to investigate whether LRCs are long-
lived, and phenotype their adult expression. The distri-
bution of LRCs in the adult prostate was similar to that
of the P5 prostates, with more numerous and more
strongly labeled LRCs in prostatic ducts as compared to
the secretory epithelium. We found that 0.48 ± 0.08%
(mean ± SD) of the distal epithelium of the prostate
lobes contained long-lived and slow-cycling LRCs,
Fig. 3 IF analysis of the distribution of LRCs and co-expression of SC markers in sagittal sections of postnatal day 5 (P5) mouse prostates. a A
cartoon of a sagittal P5 section; bladder and urethra (indicated in yellow), stroma (light blue), sphincter (Sp; grey), vas deferens (VD) and ejaculatory
duct (Ed) (both black), ejaculatory sinus (ES; orange), seminal vesicle (SV; brown), and the ventral prostate (VP; dark blue), dorso-lateral prostate (DLP;
green), and anterior prostate (AP; red). b–d are composite images of serial sagittal HTX stained sections, where ducts draining from a specific lobe are
indicated by the addition of a ‘d’ to the lobular abbreviation. Frozen sections were subjected to antibodies against Sca-1 (red) and CK14 (green) (e, f),
CD133 (green) (g), TROP-2 (green) and BrdU (red) (h), Sca-1 (red) and BrdU (green) (i), CD44 (red) and BrdU (green) (j–l), c-kit (red) and BrdU (green) (m, o),
c-kit (red) and Sca-1 (green) (n), and KRT-7 (red) and BrdU (green) (p). Sca-1 (e, f, i) and TROP-2 (h) were highly expressed in basal and luminal cells of
ducts draining into the ES and urethra. The mesenchyme surrounding these proximal ducts was positive for CD133 expression (g). Sagittal sections
clearly demonstrated that LRCs were more numerous and more strongly labeled in terminal draining ducts in or close to where the ES fuses with the
urethra (h, j, k), whereas more distal structures contained fewer and less bright LRCs (h, k). The number and intensity of epithelial LRCs further abruptly
decreased at the border of the Sp, where the ducts cross to enter the prostate lobes (i, p; arrows indicate luminal, whereas arrowheads indicates a basal
location). At this border, many putative SC markers changed their distribution pattern in both epithelium and stroma, including Sca-1 (i, n), TROP-2 (h),
CD44 (k), c-kit (n), and KRT-7 (p). Whereas Sca-1 (inset in (e) shows rare luminal Sca-1 expression of the VP from a serial section close to (e)), c-kit (n),
and KRT-7 (p) expression was rare in distal epithelium of all lobes, we found TROP-2 to be more commonly expressed in the VP when compared to
other lobes (h). CD133 was upregulated in the distal DLP (arrow, g) of P5 prostates, and whereas CD44 showed high expression in distal epithelium of
the DLP (k) and AP (arrows and inset in k), CD44 was downregulated in distal luminal cells of the VP (k, l), but not in the basal cells (arrows, l).
Additionally, VP ducts showed upregulation of CD44 in the basal cell layer (j, k) in P5 prostates. LRCs strongly reactive for BrdU in the prostate
epithelium were found to express the putative SC markers TROP-2 (h), Sca-1 (i), CD44 (j–l), c-kit (m,o), and KRT-7 (p). Counterstaining was either HTX
(IHC) or DAPI (IF). Scale bars= 25 μm (i, o, p), 50 μm (h, j, l –n), and 100 μm (e–g, k). b–e are composite images of several micrographs
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increasing significantly (p < 0.01) to 1.40 ± 0.83% in the
proximal secretory epithelium of the adult prostate, and
that ductal epithelium contained significantly more
LRCs than proximal lobes (3.7 ± 0.47% vs. 1.40 ± 0.83%,
p < 0.01). Importantly, both basal and luminal LRCs were
detected in the secretory epithelium and ducts of the
adult prostate. Basal LRCs in the adult prostate varied
significantly between ducts and proximal epithelium
(7.89 ± 0.97% vs. 2.64 ± 0.81%, p < 0.01), and between
proximal and distal secretory epithelium (2.64 ± 0.81%
vs. 1.17 ± 0.42%, p < 0.01). Likewise, significantly more
luminal LRCs could be found in ducts when compared
to secretory lobes (ductal 1.82 ± 0.31% vs. proximal 0.22
± 0.04, p < 0.01; and ductal 1.82 ± 0.31% vs. distal 0.15 ±
0.02%, p < 0.01), but not between proximal and distal
epithelium (Fig. 4).
In an effort to better characterize adult basal and lu-
minal LRCs, we co-stained LRCs for cell lineage and SC
markers, and investigated SC protein expression in lu-
minal cells (Fig. 5). In adult prostates, KRT-8 was firmly
upregulated in virtually all luminal cells regardless of
localization (Fig. 5b), whereas candidate SC proteins ex-
hibited a restricted expression pattern broadly similar to
postnatal day 5 prostates, with a higher expression in
ducts and proximal lobes compared to distal glandular
cells (Fig. 5c; TROP-2). A notable exception was CD133,
which was strongly upregulated in distal luminal cells of
the adult prostate (Fig. 5d). CD133 was, however, not
expressed in the LRC-rich ducts and proximal segments
of prostate lobes (Fig. 5d, arrows). In fact, CD133 and
TROP-2 were mutually excluding at the proximal-distal
border of the AP (Fig. 5e). Although TROP-2 did not
differentiate between basal and luminal cells, we noted
that luminal TROP-2-positive cells showed stronger ex-
pression levels in lobes and glands that were heteroge-
neous in their AR expression (DLP and AP, but not VP).
We therefore investigated if adult LRCs expressed AR.
Indeed, in ductal (Fig. 5f ), proximal (Fig. 5g), and distal
epithelium, luminal LRCs were found to express AR, but
basal LRCs did not (Fig. 5i). Basal LRCs expressed p63,
however, (Fig. 5j) and both basal and luminal LRCs in
ducts were found to express CD44, which was highly up-
regulated in adult ducts and proximal lobes (Fig. 5k),
and only rarely expressed in distal epithelium. However,
like TROP-2, CD44 was often focal when present, and
both markers extended some distance into the distal
lobular epithelium of the VP and LP, respectively (Fig. 5c
and results not shown). We then turned to KRT-7,
which had a similar (Fig. 5l) but more restricted expres-
sion pattern compared to TROP-2 (Fig. 5m). KRT-7 was
expressed by both luminal cells (strong) and basal cells
(weak) of ducts (Fig. 5l), and, similar to TROP-2, KRT-7
expression extended some distance into the VP. How-
ever, in the lobes of the DP, LP, and AP, KRT-7 expres-
sion was restricted to rare luminal cells. Co-staining
BrdU for KRT-7 revealed many basal and luminal LRCs
positive for KRT-7 in the prostate ducts (Fig. 5n). How-
ever, the harsh BrdU detection protocol hindered the de-
tection of distal KRT-7-positive LRCs, as distal cells
generally expressed lower levels of KRT-7 and distal cells
seemed more sensitive to the acid treatment. We also
noted that ducts stained stronger for the nuclear
Fig. 4 Quantitative analysis of label-retaining cell (LRC) distribution in the adult prostate. Quantification of LRCs in the adult mouse prostate
showed that epithelial LRCs were significantly more numerous in prostatic ducts (green) (3.7 ± 0.47%, mean ± SD) as compared to both proximal
(blue) and distal (red) lobular epithelium, and that proximal epithelium contained significantly more LRCs than distal epithelium (1.40 ± 0.83% vs.
0.48 ± 0.08%). Importantly, both basal and luminal LRCs were detected in the secretory epithelium and ducts of the adult prostate. Basal LRCs in
the adult prostate varied significantly between ducts and proximal epithelium (7.89 ± 0.97% vs. 2.64 ± 0.81%, p < 0.01), and between proximal and
distal secretory epithelium (2.64 ± 0.81 vs. 1.17 ± 0.42%, p < 0.01). Likewise, luminal LRCs varied significantly between ducts and proximal/distal
epithelium (1.82 ± 0.31% vs. 0.22 ± 0.04%, p < 0.01; and 1.82 ± 0.31% vs. 0.15 ± 0.02%, p < 0.01), but not significantly between proximal and distal
epithelium. Error bars represent standard deviation (SD). **p≤ 0.01
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counterstain DAPI when compared to secretory lobes,
possibly reflecting a different chromatin state between
nonsecretory progenitor cells and mature epithelium.
We then investigated if distal KRT-7 cells were positive
for AR expression. Rare distal cells positive for KRT-7 in
the DLP (Fig. 5o) and AP typically expressed higher
levels of AR. Remarkably, both proximal lobes and ducts
of the DLP (Fig. 5o) and the AP showed higher
Fig. 5 IF and IHC analysis of the distribution of long-lived LRCs and expression of cell lineage and SC markers in the adult mouse prostate. a A
transversal HTX stained section of an adult prostate; (b) shows KRT-8 expression (green) in a consecutive section to (a), with dotted lines marking
the border between distal and proximal/ductal epithelium; the white line demarks the proximal VP, blue line demarks the proximal AP, and the
DLP is demarked in red. A yellow dotted line demarks the sphincter muscle. In (c), the abrupt decrease in TROP-2 (green) at the proximal-distal
border is indicated by arrows, and a representational magnification of BrdU (green) and TROP-2 (red) from the proximal AP is highlighted in the
inset (arrowhead, c). In contrast, CD133 (DAB) was absent from the proximal lobes and ducts (arrow, d), but strongly expressed by luminal cells of
the distal lobes (d). CD133 (green) and TROP-2 (red) expression showed some overlap at the very proximal-distal border of the AP lobes (green
arrow points distally), but was mutually excluding at the cellular level (e). f, g LRCs (green) positive for AR expression (red) (arrows, f–h). The arrow
in (i) highlights a basal LRC (green) that is negative for AR. Basal LRCs (green) expressed p63 (red) (arrow, j), and both basal (arrow) and luminal
(arrowhead) LRCs (green) in ducts were found to express CD44 (red). l KRT-7 (green) and TROP-2 (red) were co-expressed in prostate ducts. How-
ever, KRT-7 (green) had a more restricted expression pattern in distal epithelium (m) as compared to TROP-2 (red). Basal (arrowhead) and luminal
(arrow) LRCs (green) co-expressed KRT-7 (red) in prostate ducts (n). o Co-expression of KRT-7 (red) and AR (green) is seen in the dorso-lateral pros-
tate (DLP) (arrows); distal DLP epithelium is indicated by white dotted lines, and the sphincter muscle (Sp) is demarked by a yellow dotted line. Note
a rare KRT-7 and AR co-expressing cell in the distal DLP and the high frequency of co-expressing cells in the ducts and proximal DLP (o). Rare
KRT-7-expressing cells (red) in the distal AP further co-expressed high levels of AR (green) (arrow, p). The expression level of c-kit was lower in
adult prostates and the harsh BrdU protocol hindered proper IF detection of c-kit; however, using double sequential chromogenic detection, c-kit
(NBT/BCIP)-positive LRCs (DAB) could be detected (arrow, q). r A single LRC (green) co-expressing Sca-1 is indicated in the distal VP (arrow). No
LRCs (green) (arrow, s) were found positive for the proliferative marker Ki67 (red) (arrowhead, s). The majority of proliferating (Ki67; green) cells were
found in the luminal cell layer (arrow, t) and were negative for p63 (red) (arrowheads, t) expression. Counterstaining when applied was either with
HTX (IHC) or DAPI (IF). a–d are consecutive composite images of several individual photomicrographs. Scale bar = 500 μm (a–d), 25 μm (i, o, p, r),
50 μm (h, j, l–n, q), and 100 μm (e–g, k, s-t)
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expression of AR in KRT-7-positive cells as compared to
KRT-7-negative cells of distal segments (Fig. 5o). We
further noted that the number of c-kit-positive cells, like
the number of cells positive for other investigated SC
markers, increased in absolute numbers in the expanded
adult ducts and proximal lobes, and were either found
as single cells or small clusters of cells, with rare LRCs
expressing c-kit (Fig. 5q, arrow). Similarly, the total
number of Sca-1 cells was increased in ducts, and, like
TROP-2, Sca-1 expression extended some distance into
the distal part of the VP, where rare co-expression of
Sca-1 and BrdU could be detected (Fig. 5r). Next we in-
vestigated if adult LRCs proliferate, and if proliferative
cells are differentially distributed in the adult prostate.
However, no LRCs positive for the proliferative marker
Ki-67 could be detected (Fig. 5s), and no statistically
significant difference was found in the proliferative
index between proximal and distal cells (mean 0.46%,
range 0.29–0.49%), or between basal and luminal cells
(Additional file 3: Table S1). However, since luminal
cells are more numerous than basal cells in all prostate
lobes (p < 0.01), this suggests that luminal cells contrib-
ute in a proportionally higher degree than basal cells to
cell renewal in the adult mouse prostate (Fig. 5t).
Discussion
Label retention has previously been used to identify
slow-cycling label-retaining stem cells in various organs,
including the slow-cycling SCs of the small intestine [4,
5, 7, 10, 18, 24]. We now report the identification of
slow-cycling label-retaining cells in both the basal and
luminal epithelial cell layers of the mouse prostate, and
that they express several SC markers in a lobe and a
developmental-specific pattern during organogenesis
and maturity, including the novel prostate SC marker
KRT-7. Importantly, we found that LRCs were highly
expressed in the principal ducts fusing with the urethra
and ES, and that this mouse prostate ‘SC niche’ had in-
creased expression of several SC markers, as well as
higher expression of the AR compared to secretory epi-
thelium. In addition, both proximal and luminal cells ex-
pressing KRT-7 generally expressed AR at higher levels
than KRT-7-negative cells in the DLP and AP. Clearly,
early (E18.5) prostate epithelial SC are AR negative and
do not depend on AR expression during the budding
phase, a stage where AR expression is restricted to the
mesenchyme. Further, during postnatal development, the
AR was upregulated in the nonproliferating terminal
ducts, whereas the proliferative distal epithelium had no
or only low levels of AR, suggesting that developmental
epithelial proliferation does not depend directly on AR
activity, in agreement with previous studies [23]. To our
knowledge, this is the first time it has been reported that
the principal ducts and proximal lobes of the AP and
DLP in adult mice express higher levels of AR as com-
pared to distal epithelium. Ductal and proximal cells fur-
ther stained more strongly for the nuclear stain DAPI as
compared to distal epithelium, likely reflecting a differ-
ent chromatin structure and transcriptional state. We
hypothesize that prostate SCs express key stemness epi-
genetic chromatin-modifying enzymes allowing self-
renewal in conjunction with epigenetic modulation of
cell-lineage transcription factors, regulating their activity
as transcriptional activators or repressors and thus pre-
determining their cell fate. It is well recognized that the
AR has both growth promoting and suppressive activity
during development and maturity [25], and that addition
of androgens to PCa cell lines induce a bell-shaped pro-
liferative response, where low levels induce proliferation,
and higher levels inhibit cell division but stimulate bio-
synthesis of prostatic fluid components [6, 11]. We have
earlier shown that the AR may function directly as a
transcriptional repressor by recruiting the repressor pro-
tein REST (RE1-silencing transcription factor), and that
this complex mediates cell cycle repression, and that
REST nuclear displacement in PCa is associated with a
poor prognosis [33]. The co-expression of nuclear AR
and several SC markers found here further suggests that
the AR does not necessarily commit the cell to terminal
differentiation, or that the AR downregulates SC genes.
Rather, AR may, together with environmental signals
and chromatin modulators, mediate transcriptional ac-
tivation and repression of key genes involved in self-
renewal, differentiation, and biosynthesis. Indeed, it
has been reported that AR splice variants can upregu-
late several SC genes in PCa [19]. We propose that
AR-mediated repression in luminal progenitors is
deregulated early on in prostate carcinogenesis, leading to
increased self-renewal and generation of daughter cells.
Epigenetic drift may further give rise to clones with differ-
ent AR transcriptional programs, giving different selective
advantages during carcinogenesis and progression, and
serve as a basis for heterogeneity in PCa and prostate can-
cer stem cells [8].
The role of the expression of KRT-7 in prostate SC
biology warrants further investigations. Intermediate fila-
ment proteins and cytokeratin expression and modula-
tion have been shown to be crucial during development,
wound repair, migration, and cell remodeling, as well as
in cell division and in neoplasia. Most historical studies
have noted that immunoreactivity for KRT-7 in PCa typ-
ically occurs in rare individual cells within otherwise
nonreactive tumor areas but, due to high cut-off values
(5% or higher) in previous studies, most PCas have been
reported as negative for KRT-7 [28]. However, Goldstein
[13] investigated an unusually large number of PCas and
frequency of KRT-7 expression, and reported that KRT-
7-positive cases increased with higher Gleason score. In-
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depth studies on the exact distribution and expression of
KRT-7 in primary PCa and in progressing metastatic dis-
ease may validate and extend results regarding if KRT7
alone or together with luminal (e.g., AR) or SC surface
proteins may serve as a prognostic histopathological or
circulating tumor cell marker.
The neuroendocrine cell type is the first cell lineage to
differentiate during prostate organogenesis [2], and these
cells are thought to be long-lived. By labeling slow-
cycling cells, there is a risk that cells that are long-lived
and that withdraw from the cell cycle and terminally dif-
ferentiate during early development will retain the label,
and result in ‘over-labeling’ of cells. However, in our ex-
periments, mature neuroendocrine cells expressing chro-
mogranin A were all negative for BrdU, suggesting that
this hypothetical limitation does not apply to the current
report. Alternatively, neuroendocrine cells form outside
the prostate prior to our labeling experiment, and mi-
grate into the prostate during organ formation, as previ-
ously suggested [2]. A similar caution for label-retaining
assays is that cells that proliferate slowly may not prolif-
erate during the pulse phase, and thus not incorporate
the label, and result in ‘under-labeling’, or false negative
number of cells—e.g., if adult (injured) organs are pulsed
and transit amplifying rather than SCs are recruited for
the repair process. Here, we pulsed prostates during or-
ganogenesis, and thus hypothetically during maximal
tissue-specific SC proliferation. Further, depending on
location, tissue-specific SCs may withdraw from the cell
cycle at different time points or proliferate more slowly
during development. SCs contributing to more proxim-
ally located structures in relation to the original SC
source/pool may retain more label than SCs that migrate
with, and continue to contribute to, structures more dis-
tally to the original SC pool during development. This
was also seen in our results, explaining the presence of a
gradient with stronger and more numerous LRCs more
proximally than distally to the urethra, and suggesting
that distal LRCs have undergone more cell divisions
(‘rapidly proliferating’ SCs) than proximal LRCs. This
may have consequences for carcinogenesis, since more
distal SCs may have accumulated more mutations. In-
deed, in the human prostate, cancer is most frequently
developed in the peripheral zone [29].
Our results are consistent with previously reported
data in the literature. Tsujimura et al. [36] pulsed and
androgen-supplemented castrated (‘injured’) prepubertal
animals with BrdU during pubertal development, and re-
ported a proximal-distal gradient of LRCs in the murine
prostate. However, they reported that about 50% of epi-
thelial cells (25% each of basal and luminal cells)
retained label in the proximal regions of the dorsal pros-
tate, a figure much higher than in the current study.
This may be due an ‘over-labeling’ in the previous study,
resulting from a too prolonged pulse period in an at-
tempt to effectively label not only transit-amplifying cells
but also quiescent SCs in the mature prostate. In the
current study, we further report several candidate SC
markers expressed by LRCs during development, and
that these change dynamically during development. The
SC markers differed not only depending on developmen-
tal stage, but also on location within the lobes and tissue
(proximal-distal). These results suggests that SC proteins
may have different roles depending on location and de-
velopmental stage, and that caution should be given
when using the presence or lack of a given SC marker as
identifiers of SC based on conditions other than those
investigated. CSCs, for example, are likely to encounter
a different microenvironment than normal SCs, and may
therefore up- or downregulate proteins reported as
tissue-specific SC markers. Our results suggest that the
ontogeny of adult prostate SCs and cell lineage-specific
cells is a dynamic developmental process, and that not
only the basal cell layer but also the luminal epithelium
contains slow-cycling LRCs. However, luminal LRCs
were generally less intensely labeled than basal LRCs,
suggesting that either luminal LRCs are derived from
basal LRCs, or that basal and luminal cells have separate
progenitors to maintain their lineages, and that luminal
LRCs proliferate more frequently during organogenesis.
Our results, together with cell lineage tracing experi-
ments, supports the former hypothesis [26], but as sug-
gested by the study by Ousset et al. [26], adult prostate
SCs may preferentially be monopotent.
It has previously been reported that castration-resistant
cells expressing the homeobox protein Nkx3-1, and that
express luminal markers including cytokeratin-18, can
survive castration and re-initiate growth [12]. A crucial
question is if the human prostate harbors luminal SCs and
if such cells are involved in carcinogenesis and relapse of
castration-resistant tumors. Notably, in long-term cas-
trated prostates, luminal proliferation becomes more com-
mon than basal cell proliferation [38], and the authors
suggested that human luminal cells may self-renew.
Conclusions
Our results suggest that there are separate basal and
luminal stem cell populations in the prostate. In castration-
resistant PCa, the AR pathway is still active despite andro-
gen deprivation therapy [3]. Our results support the idea
that AR-expressing luminal stem-like cells could function
as cancer-initiating and relapse-initiating cells in castration-
resistant prostate tumors, suggesting that novel strategies
targeting this cell population should be considered in the
treatment of prostate cancer. Additionally, our results sup-
port the notion that neuroendocrine cells are formed prior
to prostate organ development.
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